Regional map of medicines
Mexico
84,058people on antiretroviral treatment (2013)
82 %treatment coverage (2013)
Mixedhealth insurance model
Antiretroviral medicines (2013)
| Medicine | Unit price (US$) | Cost per person per year (US$) | Patent in force | Data protection | Monopoly | Possible savings per person per year (US$) |
|---|---|---|---|---|---|---|
| Abacavir 300 mg | 1.13 | 822 | No | No | No | 652 |
| Atazanavir 300 mg | 10.42 | 3,804 | Yes | No | Yes | 3,573 |
| Etravirina 100 mg | 5.02 | 7,327 | Yes | No | Yes | 6,859 |
| Lopinavir Ritonavir 200mg - 50 mg | 0.59 | 863 | Yes | No | Yes | 495 |
| Raltegravir 400 mg | 17.97 | 13,117 | Yes | No | Yes | 11,365 |
| Emtricitabina Tenofovir 200mg - 300 mg | 7.98 | 2,913 | Yes | No | Yes | 2,816 |
| Maraviroc 300 mg | — | — | Yes | No | Yes | — |
| Emtricitabina-tenofovir-efavirenz 600 mg - 300 mg - 200 mg | 9.3 | 3,393 | Yes | No | Yes | 3,210 |
Epidemiological data
| Year | People on treatment | People without treatment | Treatment coverage |
|---|---|---|---|
| 2013 | 84,058 | 103,000 | 82 % |
Health coverage
- Insurance model
- Mixed (subsidized and contributive)
- Provision of antiretrovirals
- Free of charge. Provided by each sub-system
- Procurement of antiretrovirals
- Centralized
The data were provided by RedLAM member organizations at the time; each table shows the year.